
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio is a clinical stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases such as Geographic Atrophy and Stargardt disease type 1. The company's lead product candidate, tinlarebant, has received multiple designations from both the FDA and Japanese regulatory agencies and is expected to achieve FDA approval in 1Q27. The company also has a successful and ongoing Phase 3 trial for tinlarebant, with positive interim data expected in 2H26. Belite Bio's strong financials and potential for multiple billions in revenue from tinlarebant make it a solid investment choice with a current buy rating and a $200 price target.
Bears say
Belite Bio is a biopharmaceutical company with high potential in developing innovative therapies for degenerative retinal diseases and metabolic diseases. However, the company is currently in the clinical stage and has no product revenue, and its stock performance is heavily reliant on the success of its lead product candidate, tinlarebant, which is facing a highly competitive landscape in the market. Additionally, the company may face challenges in securing sufficient funding for its ongoing and future clinical trials and potential commercialization of its products, which may impact its long-term growth prospects.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares